Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study

Medicine and Dentistry

• Health Care Cost 100%
• Plasmodium Vivax Malaria 75%
• Primaquine 58%
• Patient 50%
• Screening 33%
• Household 33%
• Glucose-6-Phosphate Dehydrogenase Deficiency 33%
• Therapeutic Procedure 25%
• Ensure 16%
• Liver 16%
• Aptitude 8%
• Diagnosis 8%
• Combination Therapy 8%
• Blood 8%
• Malaria 8%
• Patient Compliance 8%
• Glucose 6 Phosphate Dehydrogenase 8%
• Sensitivity Analysis 8%
• Horn 8%

Nursing and Health Professions

• Primaquine 58%
• Screening 33%
• Glucose 6 Phosphate Dehydrogenase Deficiency 33%
• Electric Potential 16%
• Ensure 16%
• Health Care Personnel 16%
• Procedures 8%
• Diagnosis 8%
• Combination Therapy 8%
• Parameters 8%
• Malaria 8%
• Plasmodium Vivax Malaria 8%
• Patient Compliance 8%
• Sensitivity Analysis 8%
• Glucose 6 Phosphate Dehydrogenase 8%
• Cost Control 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Plasmodium Vivax Malaria 75%
• Primaquine 58%
• Glucose 6 Phosphate Dehydrogenase Deficiency 33%
• Parasite 16%
• Ensure 16%
• Elimination 16%
• Malaria 8%
• Glucose 6 Phosphate Dehydrogenase 8%